Relaunch of TruScreen Devices in Xinjiang Uygur Region

NZX/ASX Announcement

10 August 2022

China Distributor Relaunches TruScreen devices in Xinjiang Uygur Autonomous Region

Key Highlights
• TruScreen distributor Beijing Siweixiangtai Tech Co Ltd (SWXT) has relaunched distribution for the Xinjiang Uygur Autonomous Region (UAR)
• Project was previously put on hold and further delayed by COVID
• Xinjiang Regional price approval for the TruScreen device was previously approved for Xinjiang UAR in 2020
• Xinjiang UAR in China’s far north-west has 26 million people over a vast area of 1.7m Km²
• Initial order of 20 TruScreen (China assembled) cervical cancer screening devices and 12,960 SUS has been delivered

TruScreen Group Limited (NZX/ASX: TRU) (‘TruScreen’ or ‘the Company’) is pleased to announce that its China distributor Beijing Siweixiangtai Technology Company Ltd (SWXT) has relaunched distribution of TruScreen cervical cancer screening device to Xinjiang Uygur Autonomous Region.

With easing of COVID restrictions, the relaunch of distribution in Xinjiang UAR resumes the policy focus of China’s Central and Provincial governments to continue with their national cervical cancer screening programmes to achieve the World Health Organisation’s strategic screening targets by 2030 and of eliminating cervical cancer by the end of the century.

The Xinjiang UAR has a population of 26 million spread over an area of 1.7 million Km². This vast area has many ethnic minority groups in remote locations with the Xinjiang UAR government providing special funding for cancer screening programmes.

The TruScreen cervical cancer screening device is ideally suited for Xinjiang UAR and has significant advantages in undertaking cervical cancer screening programmes in this vast area with many remote locations. The ability to provide a real time result with a robust TruScreen cervical cancer screening device, without the need for laboratory infrastructure, will support the UAR government’s programme of improving the lives of women in ethnic minorities.

In addition to the 912 hospitals in Xinjiang UAR, there are 16,588 community medical centres, a key target market for use of the TruScreen device.

TruScreen has recently delivered from its China based manufacturing facility, 20 TruScreen cervical cancer screening devices, and 12,960 SUS to commence this programme.

TruScreen CEO Juliet Hull said: “with a population of over 1.4 billion people, China remains the most established and significant market for TruScreen. The strategic decision to establish a manufacturing, together with service and recalibration facilities in China, is providing our distributor with the competitive advantage to expand their market reach within the country, with a locally manufactured device ”.

This announcement has been approved by the Board.
-ENDS-


For more information, visit www.truscreen.com or contact:
Juliet Hull
Chief Executive Officer
[email protected]

Guy Robertson
Chief Financial Officer
[email protected]

Julia Maguire
Investor Relations
[email protected]
+61 2 8999 3699

---

Announcement PDF